Progress of targeted therapy in diffuse large B-cell lymphoma: reports in the 55th ASH annual meeting
10.3760/cma.j.issn.1009-9921.2014.01.005
- VernacularTitle:弥漫大B细胞淋巴瘤靶向药物治疗进展:第55届美国血液学会年会报道
- Author:
Xuhua ZHANG
;
Yongping SONG
- Publication Type:Journal Article
- Keywords:
Lymphoma,large B-cell,diffuse;
Targeted therapy;
ASH annual meeting
- From:
Journal of Leukemia & Lymphoma
2014;23(1):9-11
- CountryChina
- Language:Chinese
-
Abstract:
With the further study on heterogeneity and molecular mechanism of diffuse large B-cell lymphoma (DLBCL),many novel targeted drugs have been developed,which also showed clinical benefit in early-stage studies.Therapeutic targets for DLBCL mainly include the surface antigens of B lymphocyte,B cell receptor signaling and the cellular microenvironment.Several new clinical trials about targeted therapy for DLBCL had been reported in the 55th ASH annual meeting,and the results were encouraging.The advances in this field will be summarized in this paper based on the new reports in the 55th ASH annual meeting.
